To compare the effectiveness of cabergoline and medroxyprogesterone acetate in the treatment of uterine adenomyosis

comparative effectiveness of cabergoline and medroxyprogesterone acetate in the treatment of adenomyosis: a randomised,open-label, parellal arm, controlled clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024422

Enrollment

Registered

2020-04-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N719- Inflammatory disease of uterus, unspecified

Interventions

Intervention1: cabergoline: T. CABERGOLINE 0.5mg twice weekly for 3 months in adenomyosis patients Control Intervention1: Inj. medroxyprogesterone acetate: inj. medroxyprogesterone acetate 150mg/ml on

Eligibility

Inclusion criteria

Inclusion criteria: 1)age between 18-50 with complaints of chronic pelvic pain 2)USG suggestive of Adenomyosis 3)consenting to participate in the study 4) use of barrier contraception or sexual abstinence during study period.

Exclusion criteria

Exclusion criteria: 1) Women attempting pregnancy or currently pregnant 2) less than six months postpartum 3)lactating mothers

Design outcomes

Primary

Measure	Time frame
it is expected that patients who receive cabergoline may have reduction in the symptoms of adenomyosis.Timepoint: at the end of 8 weeks	—

Secondary

Measure	Time frame
nilTimepoint: nil	—

Countries

India

Contacts

Public ContactDr Maitrayee Sen

SRM Institute of science and technology

melvingeorge2003@gmail.com9894133697

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026